
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNV2pYeThINDdGbHhRWmVrblMwNGNwSXVkdDY0Z1RlakZ2VkVveWxHUFN1TnR3UFQxVUZ3WHBjYWVUN0FYUG41V1FLSEFMb25oY01Ra3IxSDBNNmxRRXJ5UGRiTFdldy1BQ0NpQ2hFWVlYeFhqN3B4dEdxVkR2QmJtUmdaNlhHN2dCRnBhLUQ1NE1PakRibE5XdzBLZHhUVm5YZk55SzA5TmpSREU?oc=5" target="_blank">Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome</a>&nbsp;&nbsp;<font color="#6f6f6f">Yahoo Finance</font>
